Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study

Annalisa Mondi; Massimiliano Fabbiani; Nicoletta Ciccarelli; Manuela Colafigli; Alessandro D'Avino; Alberto Borghetti; Roberta Gagliardini; Roberto Cauda; Andrea De Luca; Simona Di Giambenedetto

doi:10.1093/jac/dkv037

Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study

Annalisa Mondi
, Massimiliano Fabbiani^*
, Nicoletta Ciccarelli
, Manuela Colafigli
, Alessandro D'Avino
, Alberto Borghetti
, Roberta Gagliardini
, Roberto Cauda
, Andrea De Luca
, Simona Di Giambenedetto

^*Corresponding author

Research output: Contribution to journal › Article

31 Citations (Scopus)

Abstract

AtLaS was a single-arm pilot study that demonstrated promising efficacy and safety of treatment simplification to a dual regimen with atazanavir/ritonavir + lamivudine in virologically suppressed HIV-positive patients. Here, we report data from the 144 week follow-up.

Original language	English
Pages (from-to)	1843-1849
Number of pages	7
Journal	Journal of Antimicrobial Chemotherapy
Volume	70
Issue number	6
DOIs	https://doi.org/10.1093/jac/dkv037
Publication status	Published - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Pharmacology
Microbiology (medical)
Infectious Diseases
Pharmacology (medical)

Keywords

antiviral
combined antiretroviral therapy
dual therapy

Access to Document

10.1093/jac/dkv037

Cite this

Mondi, A., Fabbiani, M., Ciccarelli, N., Colafigli, M., D'Avino, A., Borghetti, A., Gagliardini, R., Cauda, R., De Luca, A., & Di Giambenedetto, S. (2015). Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study. Journal of Antimicrobial Chemotherapy, 70(6), 1843-1849. https://doi.org/10.1093/jac/dkv037

@article{8f8baea8f34d4f77b38a417660cf48c1,

title = "Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study",

abstract = "AtLaS was a single-arm pilot study that demonstrated promising efficacy and safety of treatment simplification to a dual regimen with atazanavir/ritonavir + lamivudine in virologically suppressed HIV-positive patients. Here, we report data from the 144 week follow-up.",

keywords = "antiviral, combined antiretroviral therapy, dual therapy, antiviral, combined antiretroviral therapy, dual therapy",

author = "Annalisa Mondi and Massimiliano Fabbiani and Nicoletta Ciccarelli and Manuela Colafigli and Alessandro D'Avino and Alberto Borghetti and Roberta Gagliardini and Roberto Cauda and \{De Luca\}, Andrea and \{Di Giambenedetto\}, Simona",

year = "2015",

doi = "10.1093/jac/dkv037",

language = "English",

volume = "70",

pages = "1843--1849",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "6",

}

Mondi, A, Fabbiani, M, Ciccarelli, N, Colafigli, M, D'Avino, A, Borghetti, A, Gagliardini, R, Cauda, R, De Luca, A & Di Giambenedetto, S 2015, 'Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study', Journal of Antimicrobial Chemotherapy, vol. 70, no. 6, pp. 1843-1849. https://doi.org/10.1093/jac/dkv037

Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study. / Mondi, Annalisa; Fabbiani, Massimiliano; Ciccarelli, Nicoletta et al.
In: Journal of Antimicrobial Chemotherapy, Vol. 70, No. 6, 2015, p. 1843-1849.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study

AU - Mondi, Annalisa

AU - Fabbiani, Massimiliano

AU - Ciccarelli, Nicoletta

AU - Colafigli, Manuela

AU - D'Avino, Alessandro

AU - Borghetti, Alberto

AU - Gagliardini, Roberta

AU - Cauda, Roberto

AU - De Luca, Andrea

AU - Di Giambenedetto, Simona

PY - 2015

Y1 - 2015

N2 - AtLaS was a single-arm pilot study that demonstrated promising efficacy and safety of treatment simplification to a dual regimen with atazanavir/ritonavir + lamivudine in virologically suppressed HIV-positive patients. Here, we report data from the 144 week follow-up.

AB - AtLaS was a single-arm pilot study that demonstrated promising efficacy and safety of treatment simplification to a dual regimen with atazanavir/ritonavir + lamivudine in virologically suppressed HIV-positive patients. Here, we report data from the 144 week follow-up.

KW - antiviral

KW - combined antiretroviral therapy

KW - dual therapy

KW - antiviral

KW - combined antiretroviral therapy

KW - dual therapy

UR - https://publicatt.unicatt.it/handle/10807/68424

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84930517019&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84930517019&origin=inward

U2 - 10.1093/jac/dkv037

DO - 10.1093/jac/dkv037

M3 - Article

SN - 0305-7453

VL - 70

SP - 1843

EP - 1849

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 6

ER -